Filing Flows › Procept BioRobotics (PRCT) › Q3 2026 › vs Q2 2026
Procept BioRobotics (PRCT) Q3 2026 vs Q2 2026 (quarter over quarter)
Procept BioRobotics's revenue rose $3.8M (+4%) from $94.5M in Q2 2026 to $98.3M in Q3 2026.
Procept BioRobotics, Q3 2026: revenue $98.3M (+18% year over year), operating margin -27.9%, net loss $26.5M, operating cash flow −$9.0M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $98.3M | $94.5M | $3.8M | +4% |
| Other income, net | $802K | $623K | $179K | +29% |
| Income tax benefit | $58K | −$94K | $152K | — |
| Net loss | $26.5M | $26.9M | −$345K | -1% |
| Costs & expenses | $126M | $122M | $3.7M | +3% |
| Operating costs | $126M | $122M | $3.8M | +3% |
| Cost of revenue | $33.1M | $32.1M | $1.0M | +3% |
| Research & development | $20.0M | $20.1M | −$90K | -0.4% |
| SG&A | $72.5M | $69.7M | $2.8M | +4% |
| Operating cash sources | $26.6M | $35.8M | −$9.2M | -26% |
| Depreciation & amortization | $2.5M | $2.0M | $551K | +28% |
| Share-based compensation | $15.1M | $14.5M | $546K | +4% |
| Cash used in operations | $9.0M | $19.3M | −$10.3M | -53% |
| Net loss absorbed | $26.5M | $26.9M | −$345K | -1% |
| Working capital & other | $89K | $8.9M | −$8.8M | -99% |
Questions
How much did Procept BioRobotics's revenue grow quarter over quarter in Q3 2026?
Procept BioRobotics's revenue rose $3.8M (+4%) from $94.5M in Q2 2026 to $98.3M in Q3 2026.